No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Apr 2004


    View All Author Information


    We evaluated expectant management of prostate cancer with definitive treatment deferred until evidence of cancer progression in men with low risk, localized cancers.

    Materials and Methods:

    We retrospectively reviewed prospectively entered data base records. Patients with low risk cancer who were eligible for definitive therapy but chose deferred management between 1984 and 2001 composed the cohort. Followup included regular evaluations to detect progression by prostate specific antigen (PSA), digital rectal examination, transrectal ultrasound and prostate biopsy. Objective progression was defined by a point scale of changes in prognostic factors. Definitive treatment was recommended in patients with objective progression.


    The cohort comprised 88 patients with clinical stages T1–2, NX0, M0 prostate cancer, a mean age of 65.3 years and a mean initial PSA of 5.9 ng/ml. Systematic biopsy, which was repeated after the initial diagnostic biopsy, showed no cancer in 61% of cases. During a median followup of 44 months 22 patients had progression. Factors that predicted progression were repeat biopsy showing cancer (p = 0.004) and initial PSA (p = 0.014). Actuarial 5 and 10-year progression-free probabilities were 67% and 55%, respectively. Of the 31 patients treated 17 underwent radical prostatectomy, 13 received radiation therapy and 1 received androgen ablation. Seven men who did not show objective progression were treated because of anxiety. Only 1 patient, who was treated with radiation therapy, had biochemical recurrence.


    Deferred therapy may be a feasible alternative to curative treatment in select patients with favorable, localized prostate cancer. About half of these patients remain free of progression at 10 years and definitive treatment appeared effective in those with progression. Absent cancer on repeat needle biopsy identified cases highly unlikely to progress.


    • 1 : Results of conservative management of clinically localized prostate cancer. N Engl J Med1994; 330: 242. Crossref, MedlineGoogle Scholar
    • 2 : Long-term survival among men with conservatively treated localized prostate cancer. JAMA1995; 274: 626. Crossref, MedlineGoogle Scholar
    • 3 : High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA1992; 267: 2191. Google Scholar
    • 4 : Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol1996; 155: 816. LinkGoogle Scholar
    • 5 : Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer1998; 82: 342. Google Scholar
    • 6 : Prospective, conservative management of localized prostate cancer. Cancer1992; 70: 307. Google Scholar
    • 7 : Expectant management of clinically localized prostatic cancer. J Urol1994; 152: 1761. AbstractGoogle Scholar
    • 8 : Long-term impact of conservative management on localized prostate cancer. A twenty-year experience in Japan. Urology1993; 42: 520. Google Scholar
    • 9 : A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med2002; 347: 781. Google Scholar
    • 10 : Nonparametric estimation from incomplete observations. Am Stat Assoc J1958; 53: 457. Google Scholar
    • 11 : Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol2002; 167: 1231. LinkGoogle Scholar
    • 12 : Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol2002; 167: 1664. LinkGoogle Scholar
    • 13 : Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Crossref, MedlineGoogle Scholar
    • 14 : The role of serial free/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer. BJU Int2002; 89: 703. Google Scholar
    • 15 : Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol2001; 166: 1688. LinkGoogle Scholar
    • 16 : Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol2001; 25: 657. Google Scholar
    • 17 : The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer2002; 94: 1692. Google Scholar
    • 18 : Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA1992; 267: 2215. Crossref, MedlineGoogle Scholar
    • 19 : Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J Urol1998; 159: 1243. LinkGoogle Scholar
    • 20 : A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst1998; 90: 766. Crossref, MedlineGoogle Scholar

    From the Department of Urology, Memorial Sloan-Kettering Cancer Center (MIP, EL-C, MO, PTS), New York, New York, Department of Surgery, University of Sydney (MIP), Sydney, Australia, and Departments of Urology (DTD) and Pathology (TW), Baylor College of Medicine, Houston, Texas